Translationally controlled tumor protein from Madurella mycetomatis, a marker for tumorous mycetoma progression
- PMID: 16849514
- DOI: 10.4049/jimmunol.177.3.1997
Translationally controlled tumor protein from Madurella mycetomatis, a marker for tumorous mycetoma progression
Abstract
About 40 years ago Abs against the fungus Madurella mycetomatis were first demonstrated to be present in eumycetoma patients, a disease characterized by tumorous swellings. To date nothing is known about the individual immunoreactive Ags present in this fungus. In the present study, we identify its first immunogenic Ag, a protein homologous to the translationally controlled tumor protein (TCTP), a well-conserved histamine release factor in a range of eukaryotes. The gene for this Ag was demonstrated to be present in two variants in M. mycetomatis, with 13% aa difference between the two proteins encoded. In vitro, TCTP was secreted into the culture medium. In vivo, it was found to be expressed on hyphae present in developing stages of the eumycetoma-characteristic black grain. Significant IgG and IgM immune responses, against the whole protein and selected M. mycetomatis-specific peptides, were determined. The Ab levels correlated with lesion size and disease duration. Overall, the patients with the largest lesions had the highest Ab level, which lowered with decreasing size of the lesion. After 6-15 years of disease duration the Ab levels were the highest. TCTP is the first well-characterized immunogenic Ag, simultaneously the first monomolecular vaccine candidate, identified for the fungus M. mycetomatis.
Similar articles
-
Fructose-bisphosphate aldolase and pyruvate kinase, two novel immunogens in Madurella mycetomatis.Med Mycol. 2012 Feb;50(2):143-51. doi: 10.3109/13693786.2011.593005. Epub 2011 Jul 5. Med Mycol. 2012. PMID: 21728753
-
VNTR confirms the heterogeneity of Madurella mycetomatis and is a promising typing tool for this mycetoma causing agent.Med Mycol. 2019 Jun 1;57(4):434-440. doi: 10.1093/mmy/myy055. Med Mycol. 2019. PMID: 30085253
-
Madurella mycetomatis grains within a eumycetoma lesion are clonal.Med Mycol. 2022 Jul 29;60(7):myac051. doi: 10.1093/mmy/myac051. Med Mycol. 2022. PMID: 35833294 Free PMC article.
-
Mycetoma caused by Madurella mycetomatis: a completely neglected medico-social dilemma.Adv Exp Med Biol. 2013;764:179-89. doi: 10.1007/978-1-4614-4726-9_15. Adv Exp Med Biol. 2013. PMID: 23654067 Review.
-
Mycetoma caused by Madurella mycetomatis: a neglected infectious burden.Lancet Infect Dis. 2004 Sep;4(9):566-74. doi: 10.1016/S1473-3099(04)01131-4. Lancet Infect Dis. 2004. PMID: 15336224 Review.
Cited by
-
Use of immunoblotting in testing Madurella mycetomatis specific antigen.Trans R Soc Trop Med Hyg. 2016 May;110(5):312-6. doi: 10.1093/trstmh/trw023. Trans R Soc Trop Med Hyg. 2016. PMID: 27198216 Free PMC article.
-
Reconstructive surgery for mycetoma: Preliminary algorithm and a systematic review.JPRAS Open. 2024 Feb 10;40:130-137. doi: 10.1016/j.jpra.2024.02.002. eCollection 2024 Jun. JPRAS Open. 2024. PMID: 38854620 Free PMC article. Review.
-
Association of eumycetoma and schistosomiasis.PLoS Negl Trop Dis. 2013 May 23;7(5):e2241. doi: 10.1371/journal.pntd.0002241. Print 2013. PLoS Negl Trop Dis. 2013. PMID: 23717704 Free PMC article.
-
Mycetoma and Chromoblastomycosis: Perspective for Diagnosis Improvement Using Biomarkers.Molecules. 2020 Jun 2;25(11):2594. doi: 10.3390/molecules25112594. Molecules. 2020. PMID: 32498471 Free PMC article. Review.
-
Immunoglobulins G, M, and A against Sporothrix schenckii exoantigens in patients with sporotrichosis before and during treatment with itraconazole.Clin Vaccine Immunol. 2007 Sep;14(9):1149-57. doi: 10.1128/CVI.00149-07. Epub 2007 Jul 18. Clin Vaccine Immunol. 2007. PMID: 17634504 Free PMC article.
MeSH terms
Substances
Associated data
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
LinkOut - more resources
Full Text Sources